BeOne Medicines (ONC) Revenue (2015 - 2026)

BeOne Medicines (ONC) has 12 years of Revenue data on file, last reported at $1.5 billion in Q1 2026.

• On a quarterly basis, Revenue rose 35.46% year-over-year to $1.5 billion in Q1 2026; TTM through Mar 2026 was $5.7 billion, a 37.44% increase from a year earlier, with the FY2025 full-year figure at $5.3 billion, up 40.23% from the prior year.
• Revenue for Q1 2026 stood at $1.5 billion, up from $1.5 billion in the prior quarter.
• Over the last five years, Revenue for ONC reached as high as $1.5 billion in Q1 2026 and fell as low as $306.6 million in Q1 2022.
• Historically, Revenue has averaged $855.4 million across 5 years, with a median of $781.3 million in 2023.
• On a YoY basis, Revenue climbed as much as 127.73% in 2022 and fell as far as 49.39% in 2022.
• Year by year, Revenue stood at $380.1 million in 2022, then jumped by 66.91% to $634.4 million in 2023, then jumped by 77.78% to $1.1 billion in 2024, then soared by 32.84% to $1.5 billion in 2025, then rose by 1.02% to $1.5 billion in 2026.
• Per Business Quant data, the three most recent Revenue figures were $1.5 billion in Q1 2026, $1.5 billion in Q4 2025, and $1.4 billion in Q3 2025.